Market Research Future
Global Human Growth Hormones Market is Expected to Register a Growth of Significant CAGR 7.50% During the Forecast Period (2018–2023)
Human Growth Hormones Market – Scenario Market Research Future (MRFR’s) latest study reveals that the Global Human Growth Hormone Market will surge at an impressive CAGR of 7.50% during the review period (2018-2023). Growth hormone deficiency falls under the list of endocrine conditions. Growth hormone deficiency is prevalent across the globe and the reasons for the condition usually vary from person to person. Though the condition is rare, its prevalence rate has increased to a noteworthy level in recent times. In many cases, brain injury has been identified as a primary cause of growth hormones deficiency. Low level of growth hormone secretion can lead to altered body composition, osteoporosis, insulin resistance, lipid abnormalities, reduced energy levels, and reduced muscle strength. Low growth hormone secretion is usually an issue that starts at a young age and if not addressed promptly, may have major implications in later stages of life. Today, the level of awareness about the condition is much higher than in the past. Modern parents show higher vigilance in monitoring their offspring’s overall physical development and are quick to react to any anomaly they observe. Increasing awareness about endocrine disorders is reflecting favourably on the global human growth hormone market. Demand for growth hormones has increased substantially. Moreover, arrival of more effective hormones has had a positive impact on the popularity of such medical products. Request Sample Copy at https://www.marketresearchfuture.com/sample_request/6494 Competitive Analysis Market Research Future (MRFR) recognizes the following companies as the key players in Human Growth Hormones Market: There are plenty of large and small market players which operate in this market all over the globe. Some of leading market players profiled in the report include Pfizer Inc., Novo Nordisk A/S, Anhui Anke Biotechnology Co. Ltd., Eli Lilly and Company, GeneScience Pharmaceuticals Co. Ltd., Genetech Inc., Novartis AG, Biopartners GmbH, Zhongshan Hygene Biopharm Co. Ltd., Merck KGaA, Ipsen S.A. and Lifetech Labs Segments: MRFR’s report offers a thorough segmental analysis of the market on the basis of brand, route of administration, application, and distribution channel. By brand, the market has been segmented into norditropin, genotropin, mumatrope, sainzen, omnitrope and others. Among these, the norditropin segment is holds the dominant share of the market and is expected retain its positing over 2023. In 2017, the segment stood at USD 1494.98 Mn and is projected to witness a double-digit CAGR during the forecast period. By application, the